

## Lenti-X™ SARS-CoV-2 Packaging Mix (No-Envelope Control)

**Catalog No(s).**  
632676

**Amount**  
6 rxns

**Lot Number**  
Specified on product label.

### Description

Lenti-X SARS-CoV-2 Packaging Mix (No-Envelope Control) provides an extremely simple and consistent one-step method for producing high-titer lentivirus particles lacking an envelope protein. No additional transfection reagent is needed because Lenti-X SARS-CoV-2 Packaging Mix (No-Envelope Control) consists of pre-aliquoted, lyophilized, single tubes of Xfect™ Transfection Reagent premixed with an optimized formulation of lentiviral packaging plasmids. High-titer virus is produced by simply reconstituting this mixture with your lentiviral transfer vector of choice in sterile water and adding it to 293T cells, e.g., Lenti-X 293T Cells (Cat. No. 632180), in a 10-cm dish.

### Package Contents

- Lenti-X SARS-CoV-2 Packaging Mix (No-Envelope Control): 6 tubes; yellow caps

### Storage Conditions

- Store Lenti-X SARS-CoV-2 Packaging Mix (No-Envelope Control) at  $-20^{\circ}\text{C}$  in the supplied foil pouch containing the desiccant sachet.
- Make sure to return any unused Lenti-X SARS-CoV-2 Packaging Mix (No-Envelope Control) to the supplied foil pouch containing the desiccant sachet, and store at  $-20^{\circ}\text{C}$ .

### Shelf Life

- 1 year from date of receipt under proper storage conditions.

### Shipping Conditions

- Dry ice ( $-70^{\circ}\text{C}$ )

### Product Documents

Documents for our products are available for download at [takarabio.com/manuals](https://takarabio.com/manuals)  
The following documents apply to this product:

- Lenti-X SARS-CoV-2 Packaging Single Shots Protocol-at-a-Glance

### Quality Control Data

#### Transfection Test

293T cells were transfected with plasmid DNA encoding AcGFP1 as described in the Lenti-X SARS-CoV-2 Packaging Single Shots Protocol-at-a-Glance. 48 hr post transfection, AcGFP1 expression was assessed by flow cytometry, and transfection efficiency (as determined by the percentage of 293T cells expressing AcGFP1) was demonstrated to be  $>75\%$ . The presence of virus particles in the supernatant of transfected cells was confirmed using Lenti-X GoStix Plus.

---

#### Takara Bio USA, Inc.

1290 Terra Bella Avenue, Mountain View, CA 94043, USA  
U.S. Technical Support: [technical\\_support@takarabio.com](mailto:technical_support@takarabio.com)

United States/Canada  
800.662.2566  
(102820)

Asia Pacific  
+1.650.919.7300

Europe  
+33.(0)1.3904.6880

Japan  
+81.(0)77.565.6999

# Certificate of Analysis

Cat. No. 632676

Lenti-X SARS-CoV-2 Packaging Mix (No-Envelope Control)

---

## **Sterility Test**

There was no evidence of bacterial or fungal growth after inoculation on thioglycollate medium and tryptic soy broth.

It is certified that this product meets the above specifications, as reviewed and approved by the Quality Department.

## Lenti-X™ SARS-CoV-2 Packaging Mix (No-Envelope Control)

### CATALOG NO.

632676

### NOTICE TO PURCHASER:

Our products are to be used for **Research Use Only**. They may not be used for any other purpose, including, but not limited to, use in humans, therapeutic or diagnostic use, or commercial use of any kind. Our products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without our prior written approval.

Your use of this product is also subject to compliance with the licensing requirements, listed below if applicable, and described on the product's web page at <http://www.takarabio.com>. It is your responsibility to review, understand and adhere to any restrictions imposed by these statements.

### STATEMENT 63

Use of this product is covered by one or more of the following U.S. Patent Nos. and corresponding patent claims outside the U.S.: 6,998,115; 7,427,394. This product is intended for research purposes only. It may not be used for (i) any human or veterinary use, including without limitation therapeutic and prophylactic use, (ii) any clinical use, including without limitation diagnostic use, (iii) screening of chemical and/or biological compounds for the identification of pharmaceutically active agents (including but not limited to screening of small molecules), target validation, preclinical testing services, or drug development. Any use of this product for any of the above mentioned purposes requires a license from the Massachusetts Institute of Technology.

### STATEMENT 259

This product is protected by Japanese Patent No. 6454352 and corresponding U.S. pending patent and other foreign patents pending. For further license information, please contact a Takara Bio USA licensing representative by email at [licensing@takarabio.com](mailto:licensing@takarabio.com).

### TRADEMARKS:

**©2020 Takara Bio Inc. All Rights Reserved.**

All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions.

---

#### Takara Bio USA, Inc.

1290 Terra Bella Avenue, Mountain View, CA 94043, USA  
U.S. Technical Support: [techUS@takarabio.com](mailto:techUS@takarabio.com)

#### United States/Canada

800.662.2566

#### Asia Pacific

+1.650.919.7300

#### Europe

+33.(0)1.3904.6880

#### Japan

+81.(0)77.565.6999

10/28/2020